SG11201803781XA - Treatment of retinal degeneration using progenitor cells - Google Patents

Treatment of retinal degeneration using progenitor cells

Info

Publication number
SG11201803781XA
SG11201803781XA SG11201803781XA SG11201803781XA SG11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA SG 11201803781X A SG11201803781X A SG 11201803781XA
Authority
SG
Singapore
Prior art keywords
international
cells
progenitor cells
pennsylvania
johnson
Prior art date
Application number
SG11201803781XA
Other languages
English (en)
Inventor
Ian Harris
Jing Cao
Nadine Sophia Dejneka
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201803781XA publication Critical patent/SG11201803781XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/51Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
SG11201803781XA 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells SG11201803781XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263463P 2015-12-04 2015-12-04
PCT/US2016/064336 WO2017095991A1 (fr) 2015-12-04 2016-12-01 Traitement de la dégénérescence rétinienne à l'aide de cellules progénitrices

Publications (1)

Publication Number Publication Date
SG11201803781XA true SG11201803781XA (en) 2018-06-28

Family

ID=58797699

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803781XA SG11201803781XA (en) 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells

Country Status (15)

Country Link
US (1) US20170157179A1 (fr)
EP (1) EP3384009A4 (fr)
JP (1) JP2019501888A (fr)
KR (1) KR20180088713A (fr)
CN (1) CN108291199A (fr)
AR (1) AR106913A1 (fr)
AU (1) AU2016365312A1 (fr)
BR (1) BR112018011278A2 (fr)
CA (1) CA3007198A1 (fr)
MX (1) MX2018006729A (fr)
PH (1) PH12018501045A1 (fr)
RU (1) RU2018122461A (fr)
SG (1) SG11201803781XA (fr)
TW (1) TW201729819A (fr)
WO (1) WO2017095991A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
KR102224115B1 (ko) 2020-01-10 2021-03-09 경북대학교병원 3차원 바이오프린팅 기술을 이용한 망막 세포 배양용 구조체 및 이의 활용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001855A (en) * 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
MXPA04000839A (es) * 2001-08-01 2004-05-14 Merck Patent Gesellscahft Mit Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
PL1641914T3 (pl) * 2003-06-27 2017-01-31 DePuy Synthes Products, Inc. Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
AU2008321386B2 (en) * 2007-11-15 2014-10-23 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8
JP6106159B2 (ja) * 2011-05-09 2017-03-29 アレグロ ファーマシューティカルズ インコーポレイテッドAllegro Pharmaceuticals,Inc. R−g−システイン酸ペプチドを含む医薬組成物
WO2013184976A2 (fr) * 2012-06-06 2013-12-12 Northwestern University Compositions et procédés d'induction d'une tolérance spécifique d'antigène
WO2016099949A2 (fr) * 2014-12-16 2016-06-23 Janssen Biotech, Inc. Traitement de la dégénérescence rétinienne avec des cellules progénitrices

Also Published As

Publication number Publication date
WO2017095991A1 (fr) 2017-06-08
JP2019501888A (ja) 2019-01-24
KR20180088713A (ko) 2018-08-06
BR112018011278A2 (pt) 2018-11-21
CA3007198A1 (fr) 2017-06-08
RU2018122461A (ru) 2020-01-13
AU2016365312A1 (en) 2018-05-24
CN108291199A (zh) 2018-07-17
EP3384009A4 (fr) 2019-06-12
TW201729819A (zh) 2017-09-01
MX2018006729A (es) 2018-11-09
AR106913A1 (es) 2018-02-28
US20170157179A1 (en) 2017-06-08
EP3384009A1 (fr) 2018-10-10
PH12018501045A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201806398YA (en) Optimized factor viii genes
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201807269PA (en) Filamentous fungal biomats, methods of their production and methods of their use
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809751XA (en) Egfr inhibitor compounds
SG11201811554SA (en) Antisense oligonucleotides for modulating htra1 expression
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201803642WA (en) Bacteria-based protein delivery